Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 17-31

  Marcato, Paola ^a   Dean, Cheryl A ^a   Liu, Rong Zong ^b   Coyle, Krysta M ^a   Bydoun, Moamen ^a   Wallace, Melissa ^a   Clements, Derek ^a   Turner, Colin ^a   Mathenge, Edward G ^a   Gujar, Shashi A ^a,c   Giacomantonio, Carman A ^a   Mackey, John R ^b   Godbout, Roseline ^b   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

ALDH1A1; ALDH1A3; Breast cancer; Retinoic acid; Triple negative

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; ALDEHYDE DEHYDROGENASE 1A3; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; EYA2 PROTEIN; MESSENGER RNA; MUCIN 4; PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE (NAD(P)+); TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ALDEHYDE OXIDOREDUCTASES; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; SIGNAL TRANSDUCTION; TRETINOIN;

EID: 84920611604     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.010     Document Type: Article

References (62)

1. Bachmeier B.E., Nerlich A.G., Mirisola V., Jochum M., Pfeffer U. Lineage infidelity and expression of melanocytic markers in human breast cancer. Int. J. Oncol. 2008, 33:1011-1015.
2. Balmer J.E., Blomhoff R. Gene expression regulation by retinoic acid. J.Lipid Res. 2002, 43:1773-1808.
3. Black W., Vasiliou V. The aldehyde dehydrogenase gene superfamily resource center. Hum. Genomics 2009, 4:136-142.
4. Bryan M., Pulte E.D., Toomey K.C., Pliner L., Pavlick A.C., Saunders T., Wieder R. A pilot phase i trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer. Invest. New Drugs 2011, 29:1482-1487.
5. Budd G.T., Adamson P.C., Gupta M., Homayoun P., Sandstrom S.K., Murphy R.F., McLain D., Tuason L., Peereboom D., Bukowski R.M., Ganapathi R. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res. 1998, 4:635-642.
6. Chambers A.F. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res. 2009, 69:5292-5293.
7. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., Houvenaeghel G., Extra J.M., Bertucci F., Jacquemier J., Xerri L., Dontu G., Stassi G., Xiao Y., Barsky S.H., Birnbaum D., Viens P., Wicha M.S. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16:45-55.
8. Chaturvedi P., Singh A.P., Batra S.K. Structure, evolution, and biology of the MUC4 mucin. FASEB J 2008, 22:966-981.
9. Chiesa M.D., Passalacqua R., Michiara M., Franciosi V., Di C.F., Bisagni G., Camisa R., Buti S., Tomasello G., Cocconi G. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial. Acta Biomed. 2007, 78:204-209.
10. Chung J.H., Lee H.J., Kim B.H., Cho N.Y., Kang G.H. DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Arch. 2011, 459:201-211.
11. Crooks G.E., Hon G., Chandonia J.M., Brenner S.E. WebLogo: a sequence logo generator. Genome Res. 2004, 14:1188-1190.
12. Gagnon I., Duester G., Bhat P.V. Enzymatic characterization of recombinant mouse retinal dehydrogenase type 1. Biochem. Pharmacol. 2003, 65:1685-1690.
13. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
14. Ginestier C., Wicinski J., Cervera N., Monville F., Finetti P., Bertucci F., Wicha M.S., Birnbaum D., Charafe-Jauffret E. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009, 8:3297-3302.
15. Guarnaccia V. Retinoic Acid and Breast Cancer: How to Improve the Therapeutic Effect on the Basis of Moleuclar Knowledge 2010.
16. Gudas L.J., Wagner J.A. Retinoids regulate stem cell differentiation. J.Cell Physiol. 2011, 226:322-330.
17. Hollestelle A., Schutte M. Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res. 2009, 69:7893.
18. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
19. Jia J., Parikh H., Xiao W., Hoskins J.W., Pflicke H., Liu X., Collins I., Zhou W., Wang Z., Powell J., Thorgeirsson S.S., Rudloff U., Petersen G.M., Amundadottir L.T. An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer. BMC. Med. Genomics 2013, 6:33.
20. Kang E.J., Jung H., Woo O.H., Park K.H., Woo S.U., Yang D.S., Kim A.R., Lee J.B., Kim Y.H., Kim J.S., Seo J.H. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma 2014, 61:352-362.
21. Khoury T., Ademuyiwa F.O., Chandrasekhar R., Jabbour M., Deleo A., Ferrone S., Wang Y., Wang X. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod. Pathol. 2012, 25:388-397.
22. Kim B.H., Cho N.Y., Shin S.H., Kwon H.J., Jang J.J., Kang G.H. CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma. Virchows Arch. 2009, 455:343-351.
23. Lalevee S., Anno Y.N., Chatagnon A., Samarut E., Poch O., Laudet V., Benoit G., Lecompte O., Rochette-Egly C. Genome-wide in silico identification of new conserved and functional retinoic acid receptor response elements (direct repeats separated by 5 bp). J.Biol. Chem. 2011, 286:33322-33334.
24. Lemay D.G., Hwang D.H. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J.Lipid Res. 2006, 47:1583-1587.
25. Li T., Su Y., Mei Y., Leng Q., Leng B., Liu Z., Stass S.A., Jiang F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest. 2010, 90:234-244.
26. Li X., Wan L., Geng J., Wu C.L., Bai X. Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J.Thorac. Oncol. 2012, 7:1235-1245.
27. Liu R.Z., Graham K., Glubrecht D.D., Germain D.R., Mackey J.R., Godbout R. Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am. J. Pathol. 2011, 178:997-1008.
28. Liu X., Nugoli M., Laferriere J., Saleh S.M., Rodrigue-Gervais I.G., Saleh M., Park M., Hallett M.T., Muller W.J., Giguere V. Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc. Natl. Acad. Sci. U S A 2011, A108:774-779.
29. Luo Y., Dallaglio K., Chen Y., Robinson W.A., Robinson S.E., McCarter M.D., Wang J., Gonzalez R., Thompson D.C., Norris D.A., Roop D.R., Vasiliou V., Fujita M. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 2012, 30:2100-2113.
30. Makiyama K., Hamada J., Takada M., Murakawa K., Takahashi Y., Tada M., Tamoto E., Shindo G., Matsunaga A., Teramoto K., Komuro K., Kondo S., Katoh H., Koike T., Moriuchi T. Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol. Rep. 2005, 13:673-679.
31. Mao P., Joshi K., Li J., Kim S.H., Li P., Santana-Santos L., Luthra S., Chandran U.R., Benos P.V., Smith L., Wang M., Hu B., Cheng S.Y., Sobol R.W., Nakano I. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. U S A 2013, A110:8644-8649.
32. Marcato P., Dean C.A., Pan D., Araslanova R., Gillis M., Joshi M., Helyer L., Pan L., Leidal A., Gujar S., Giacomantonio C.A., Lee P.W. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011, 29:32-45.
33. Marchitti S.A., Brocker C., Stagos D., Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 2008, 4:697-720.
34. McGrane M.M. Vitamin A regulation of gene expression: molecular mechanism of a prototype gene. J.Nutr. Biochem. 2007, 18:497-508.
35. Moreb J.S., Mohuczy D., Ostmark B., Zucali J.R. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother. Pharmacol. 2007, 59:127-136.
36. Morimoto K., Kim S.J., Tanei T., Shimazu K., Tanji Y., Taguchi T., Tamaki Y., Terada N., Noguchi S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009, 100:1062-1068.
37. Mukhopadhyay P., Lakshmanan I., Ponnusamy M.P., Chakraborty S., Jain M., Pai P., Smith L.M., Lele S.M., Batra S.K. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoS One 2013, 8:e54455.
38. Nerlich A.G., Bachmeier B.E. Density-dependent lineage instability of MDA-MB-435 breast cancer cells. Oncol. Lett. 2013, 5:1370-1374.
39. Neumeister V., Agarwal S., Bordeaux J., Camp R.L., Rimm D.L. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol. 2010, 176:2131-2138.
40. Novak P., Jensen T., Oshiro M.M., Wozniak R.J., Nouzova M., Watts G.S., Klimecki W.T., Kim C., Futscher B.W. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 2006, 66:10664-10670.
41. Park S.Y., Kwon H.J., Choi Y., Lee H.E., Kim S.W., Kim J.H., Kim I.A., Jung N., Cho N.Y., Kang G.H. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod. Pathol. 2012, 25:185-196.
42. Penzes P., Wang X., Napoli J.L. Enzymatic characteristics of retinal dehydrogenase type I expressed in Escherichia coli. Biochim. Biophys. Acta 1997, 1342:175-181.
43. Pilato B., Pinto R., De S.S., Lambo R., Paradiso A., Tommasi S. HOX gene methylation status analysis in patients with hereditary breast cancer. J.Hum. Genet. 2013, 58:51-53.
44. Resetkova E., Reis-Filho J.S., Jain R.K., Mehta R., Thorat M.A., Nakshatri H., Badve S. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res. Treat 2010, 123:97-108.
45. Rexer B.N., Zheng W.L., Ong D.E. Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells. Cancer Res. 2001, 61:7065-7070.
46. Schneider T.D., Stephens R.M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990, 18:6097-6100.
47. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
48. Schug T.T., Berry D.C., Toshkov I.A., Cheng L., Nikitin A.Y., Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR. Proc. Natl. Acad. Sci. U S A 2008, A105:7546-7551.
49. Sima A., Parisotto M., Mader S., Bhat P.V. Kinetic characterization of recombinant mouse retinal dehydrogenase types 3 and 4 for retinal substrates. Biochim. Biophys. Acta 2009, 1790:1660-1664.
50. Singletary S.E., Atkinson E.N., Hoque A., Sneige N., Sahin A.A., Fritsche H.A., Lotan R., Lu T., Hittelman W.N., Bevers T.B., Stelling C.B., Lippman S.M. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin. Cancer Res. 2002, 8:2835-2842.
51. Sladek N.E., Kollander R., Sreerama L., Kiang D.T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 2002, 49:309-321.
52. Sutton L.M., Warmuth M.A., Petros W.P., Winer E.P. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother. Pharmacol. 1997, 40:335-341.
53. Tang X.H., Gudas L.J. Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 2011, 6:345-364.
54. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N.Engl. J. Med. 1994, 330:1029-1035. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group.
55. Wardwell-Ozgo J., Dogruluk T., Gifford A., Zhang Y., Heffernan T.P., van D.R., Creighton C.J., Chin L., Scott K.L. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 2014, 33:1017-1026.
56. Yang Z.L., Yang L., Zou Q., Yuan Y., Li J., Liang L., Zeng G., Chen S. Positive ALDH1A3 and negative GPX3 expressions are biomarkers for poor prognosis of gallbladder cancer. Dis. Markers 2013, 35:163-172.
57. Yonezawa S., Goto M., Yamada N., Higashi M., Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 2008, 8:3329-3341.
58. Yonezawa S., Higashi M., Yamada N., Yokoyama S., Kitamoto S., Kitajima S., Goto M. Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol. Int. 2011, 61:697-716.
59. Zhang R.D., Fidler I.J., Price J.E. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991, 11:204-215.
60. Zhang W., Yan W., You G., Bao Z., Wang Y., Liu Y., You Y., Jiang T. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP-primary glioblastoma. Cancer Lett. 2013, 328:120-125.
61. Zhao D., McCaffery P., Ivins K.J., Neve R.L., Hogan P., Chin W.W., Drager U.C. Molecular identification of a major retinoic-acid-synthesizing enzyme, a retinaldehyde-specific dehydrogenase. Eur. J. Biochem. 1996, 240:15-22.
62. Zhu Y., Zhang J.J., Zhu R., Zhu Y., Liang W.B., Gao W.T., Yu J.B., Xu Z.K., Miao Y. The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med. Oncol. 2011, 28(Suppl. 1):S175-S184.